Boutte v. Jefferson Parish Hospital Service District No. 1
This text of 738 So. 2d 1188 (Boutte v. Jefferson Parish Hospital Service District No. 1) is published on Counsel Stack Legal Research, covering Louisiana Court of Appeal primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.
Opinion
This case arises from a petition for damages brought by Daniel Boutte, and his wife and children, alleging that Mr. Boutte contracted the Hepatitis C virus from a blood transfusion he received from the respondent, Hotel Dieu Hospital. Appellant, Daniel Boutte, appeals the trial court’s grant of the Appellee, Hotel Dieu’s, exception of prescription. For the following reasons, we reverse and remand to the trial court.
[1189]*1189 FACTS AND PROCEDURAL HISTORY
On September 27, 1995, Daniel Boutte was diagnosed with the Hepatitis C virus. Mr. Boutte was told that the likely cause of his Hepatitis C infection was blood transfusions he received from the defendants, West Jefferson Hospital, Charity Hospital, East Jefferson General Hospital, and Hotel Dieu Hospital. The instant case involves only the defendant, Hotel Dieu Hospital, from which Mr. Boutte ^received blood transfusions in December of 1981 and January of 1982. Mr. Boutte filed a Petition for Damages on July 10, 1996, within one year of his diagnosis of Hepatitis C. On October 19, 1998, the trial court granted Hotel Dieu Hospital’s Exception of Prescription.
ISSUE
The issue in the case is whether 1) Mr. Boutte’s claim is a claim under medical malpractice only, and is therefore subject to the special statute of limitations which bars medical malpractice actions which are not filed “within a period of three years from the date of the alleged act, omission, or neglect.” LSA-R.S. 9:56281; or 2) whether Mr. Boutte’s claim is an action in strict liability, which would be subject to the general one year prescription applicable to all delictual actions, and which does not commence to run until the victim knows or should know of the damage. LSA-C.C. art. 3492.2
DISCUSSION
Prior to July 15,1981, under Civil Code article 2315, a distributor of blood in Louisiana was strictly liable in tort when the blood he placed on the market created “an unreasonable risk of harm to others and, in fact, resulted in injury or disease to a human being.” DeBattista v. Argonaut-Southwest Ins. Co., 403 So.2d 26 (La.1981). Subsequent to the Supreme Court’s decision in DeBattista, the legislature added Civil Code article 2322.1 and LSA-R.S. 9:2797 granting physicians, hospitals, and blood banks immunity from strict tort liability for the screening, procurement, processing, distribution, transfusion or medical use of blood and blood components.3 These “blood shield” statutes were declared unconstitutional by the Fourth Circuit Court of Appeal in Casey v. Southern Baptist Hospital, 526 So.2d 1332 (La.App. 4 Cir.1988). However because LSA-R.S. 9:2797 was amended and reenacted by Acts 1982, No. 204, § 1, with an effective date of July 15, 19824 the court - limited its findings of unconstitutionality until July 15, 1982. Casey v. Southern Baptist Hospital, 526 So.2d at 1336.5
[1190]*1190In the instant case, Mr. Boutte received the blood transfusions from Hotel Dieu Hospital in December of 1981 and January of 1982, prior to the amendment and reenactment of the blood shield statutes.
In Branch v. Willis-Knighton Medical Center, 92-3086 (La.4/28/94), 636 So.2d 211, the Louisiana Supreme Court addressed the issue we now face and concluded that claims of plaintiffs who sustained injury, infection, or disease from contaminated blood prior to the enactment dates of Civil Code article 2322.1 and LSA-R.S. 9:2797 were not barred by the immunities provided by that legislation. The Supreme Court reasoned that:
Those plaintiffs have acquired causes of action in strict tort products liability as vested property rights protected by the guarantee of due process; the statutes enacted after the acquisition of such vested property rights cannot be retroactively applied so as to divest the plaintiffs of their vested rights in their causes of action.
Branch v. Willis-Knighton Medical Center, 636 So.2d at 213 citing, Faucheaux v. Alton Ochsner Medical Foundation Hosp., 470 So.2d 878 (La.1985).
Hotel Dieu argues the reasoning of Walker v. Bossier Medical Center, 30-715 (La.App. 2 Cir. 6/24/98), 714 So.2d 895 for the proposition that Mr. Boutte’s claim is a medical malpractice claim under LSA-R.S. 40:1299.41A(8) and therefore, under the prescriptive period of LSA-R.S. 9:5628, his claim prescribed in 1985. Even though the Walker court found that the plaintiffs claim was based in strict liability, and that strict liability for defects in blood was not abrogated until the enactment of the blood shield statutes, it nevertheless held that any such cause of action filed after the 1976 amendment to LSA-R.S. 40:1299.41A(8), albeit a claim in strict liability, was a medical malpractice action subject to the prescriptive period provided for by LSA-R.S. 9:5628.6
| initially we note that the Supreme Court in Branch stated:
The law [R.S. 9:5628] does not apply to strict tort products liability actions arising out of the sale of blood in defective condition unreasonably dangerous to the user or consumer. In fact, R.S. 9:5628 does not contain any provision that expressly or implicitly refers to strict liability or products liability. Instead, the title, “§ 5628 Actions for medical malpractice,” and all of the other earmarks of the statute indicate that the legislature intended to deal only with actions traditionally classified under the generally prevailing meaning of “medical malpractice”viz., suits based on negligence, breach of express agreement, abandonment, assault or lack of informed consent.
Branch v. Willis-Knighton Medical Center, 636 So.2d at 214.
The Walker court attempted to distinguish Branch by noting that the plaintiff in Branch received a blood transfusion prior to 1976 amendments to LSA-R.S. 40:1299.41A(8) and LSA-R.S. 40:1299.39(A)(4) which included “all legal responsibility of a health care provider arising from defects in blood, tissue, transplants, drugs and medicines, or from de[1191]*1191fects in or failures of prosthetic devices, implanted in or used on or in the person of a patient” in the definition of medical malpractice.7 Thus Walker reasoned that the plaintiffs action had prescribed under LSA-R.S. 9:5628. We decline to follow that holding. The Walker court fails to take into account the Supreme Court’s decision in Faucheaux v. Alton Ochsner Medical Foundation Hosp. and Clinic, 470 So.2d 878 (La.1985), wherein it was held that the plaintiffs cause of action, which occurred in 1981, prior to the |‘Renactment of the blood shield statutes, but after the 1976 amendment to LSA-R.S. 40:1299.41A(8), was an action, not in medical malpractice, but in strict tort liability. Id, 470 So.2d at 878.8 Thus the 1976 amendment had no effect on the Supreme Court’s reasoning.
Accordingly, we do not find the distinction made in Walker to be persuasive, and hold that the trial court erred in granting the appellee’s exception of prescription.
Mr. Boutte also argues in his brief that LSA-R.S.
Free access — add to your briefcase to read the full text and ask questions with AI
Related
Cite This Page — Counsel Stack
738 So. 2d 1188, 1999 La. App. LEXIS 2226, 1999 WL 548974, Counsel Stack Legal Research, https://law.counselstack.com/opinion/boutte-v-jefferson-parish-hospital-service-district-no-1-lactapp-1999.